ISOFLAVONES
March 22, 2021LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
March 31, 2021- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- SGLT2 inhibitors may predispose to ketoacidosis
- An update on the safety of SGLT2 inhibitors
- SGLT2 inhibitors: are they safe?
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- Extraglycemic effects of SGLT2 inhibitors: a review of the evidence
- Possible adverse effects of SGLT2 inhibitors on bone
- Risks associated with SGLT2 inhibitors: an overview
- A review on the relationship between SGLT2 inhibitors and cancer
- SGLT2 inhibitors and the diabetic kidney
- SGLT2 inhibitors and mechanisms of hypertension
- The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
- An update on SGLT2 inhibitors for the treatment of diabetes mellitus
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- Development of SGLT1 and SGLT2 inhibitors
- Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
- SGLT2 inhibitors as a therapeutic option for diabetic nephropathy
- Effects of SGLT2 inhibitors on cardiovascular outcomes
- Effects of SGLT2 inhibitors on kidney and cardiovascular function
- SGLT2 inhibitors: their potential reduction in blood pressure
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
- SGLT2 inhibitors
- SGLT2 inhibitors: the latest “new kids on the block”!
- SGLT2 inhibitors in the treatment of type 2 diabetes
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
- SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
- Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
- SGLT2 inhibitors: molecular design and potential differences in effect
- Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
- Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
- Promise of SGLT2 inhibitors in heart failure: diabetes and beyond
- Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
- SGLT2 inhibitors: benefit/risk balance
- Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
- Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans
- Metabolism of the failing heart and the impact of SGLT2 inhibitors
- SGLT2 inhibitors in the management of type 2 diabetes
- Acute kidney injury from SGLT2 inhibitors: potential mechanisms
- More evidence for SGLT2 inhibitors in heart failure
- Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
- Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors
- The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus
- Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?
- SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms
- Practical approach to initiating SGLT2 inhibitors in type 2 diabetes
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- Are SGLT2 inhibitors ready for prime time for CKD?
- Optimising the benefits of SGLT2 inhibitors for type 1 diabetes
- SGLT2 inhibitors and the kidney: effects and mechanisms
- SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
- SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
- Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
- The renal effects of SGLT2 inhibitors and a mini-review of the literature
- Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
- The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
- SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus
- SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …
- SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management
- Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
- SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
- Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
- Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives
- Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- Uric acid and the cardio‐renal effects of SGLT2 inhibitors
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
- SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update
- Renal effects of SGLT2 inhibitors: an update
- Adverse effects of SGLT2 inhibitors on bone health
- SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
- SGLT2 inhibitors in Liver Patients
- Does lower limb amputation concern all SGLT2 inhibitors?
- SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
- Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
- SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function
- Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
- The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- Synthetic strategies toward SGLT2 inhibitors
- Class effects of SGLT2 inhibitors on cardiorenal outcomes
- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
- What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
- SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice
- SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
- Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
- Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors
- SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
- Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications
- Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program
- SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
- Safety of SGLT2 inhibitors in patients with diabetes mellitus
- Diabetic ketoacidosis with SGLT2 inhibitors
- SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind …
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …
- Acute kidney injury and adverse renal events in patients receiving SGLT2–inhibitors: a systematic review and meta-analysis
- Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
- SGLT2 inhibitors: β blockers for the kidney?
- Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
- SGLT2 inhibitors and diabetic ketoacidosis—a growing concern
- The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
- SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus
- Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
- SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
- The expanding résumé of SGLT2 inhibitors
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta‐analysis
- Combination therapy with SGLT2 inhibitors for diabetic kidney disease
- Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
- SGLT2 inhibitors in T2D and associated comorbidities—differentiating within the class
- Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
- Adoption of new glucose-lowering medications in the US—the case of SGLT2 inhibitors: nationwide cohort study
- Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
- SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney …
- Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?
- The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
- Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
- Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care
- SGLT2 inhibitors: nephroprotective efficacy and side effects
- SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review
- SGLT2 inhibitors–a potential treatment for Alport syndrome
- SGLT2 inhibitors and urinary tract infections
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using …
- SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
- SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding …
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis
- Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis
- Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
- Clinical credence—SGLT2 inhibitors, diabetes, and chronic kidney disease
- Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
- SGLT2 inhibitors: practical considerations and recommendations for cardiologists
- SGLT2 inhibitors‘ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn
- Does metformin interfere with the cardiovascular benefits of SGLT2 inhibitors? Questions about its role as the cornerstone of diabetes treatment
- Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale …
- SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes
- SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials
- Risk of amputations associated with SGLT2 inhibitors compared to DPP‐4 inhibitors: a propensity‐matched cohort study
- SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
- SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
- SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
- The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
- The role of the kidney and SGLT2 inhibitors in type 2 diabetes
- Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
- Regression of left ventricular hypertrophy with SGLT2 inhibitors
- Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
- Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
- SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients
- Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
- Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm
- SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
- Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction
- The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis
- SGLT2 inhibitors: the star in the treatment of type 2 diabetes?
- ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
- Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
- Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
- Recommendations on the proper use of SGLT2 inhibitors
- Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
- Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review
- Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018
- Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
- SGLT2–inhibitors; more than just glycosuria and diuresis
- Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes
- Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: implications for clinical practice
- SGLT2 inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
- Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?
- The role of kidney in glucose homeostasis–SGLT2 inhibitors, a new approach in diabetes treatment
- Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus
- Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes
- Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review
- Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients
- CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis
- SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
- Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and …
- Minireview: are SGLT2 inhibitors heart savers in diabetes?
- SGLT2 inhibitors in the real world: too good to be true?
- Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia
- Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition
- Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
- An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent
- Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
- Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to …
- Clinical implication of SGLT2 inhibitors in type 2 diabetes
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational …
- Benefits of SGLT2 inhibitors beyond glycemic control–a focus on metabolic, cardiovascular and renal outcomes
- The Effects of SGLT2 inhibitors on Lipid Metabolism
- Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media
- Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
- The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
- Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of …
- Diabetic Agents, From Metformin to SGLT2 inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar
- Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
- Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors
- SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
- Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance
- Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
- SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
- Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches
- Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1, 3, 4-Thiadiazolylmethylphenyl glucoside congeners
- Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics
- Discovery of non-glucoside SGLT2 inhibitors
- The role of SGLT2 inhibitors in managing type 2 diabetes
- SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
- SGLT2–inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2–inhibitors in clinical practice
- How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology
- The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
- SGLT2 inhibitors for diabetes: turning symptoms into therapy.
- The sweet spot: heart failure prevention with SGLT2 inhibitors
- SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes
- Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
- Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry
- Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE
- Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors
- Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an …
- A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy …
- SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
- SGLT2 inhibitors and risk of genitourinary infections
- Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
- Update on SGLT2 inhibitors—new data released at the American Diabetes Association
- Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus
- Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk
- SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem
- SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes
- An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
- Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes
- SGLT2 inhibitors and cancer: why further evidence is required
- Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes
- Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials
- … of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide
- SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?
- Sodium‐glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta‐analysis
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta‐analysis of randomized controlled trials
- SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
- SGLT2 inhibitors and heart failure—clinical implications
- The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and …
- SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors in diabetes and microvascular complications: A Review
- When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
- … -glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review
- SGLT2 inhibitors in type 2 diabetic patients with renal function impairment slows the annual renal function decline, in a real clinical practice
- Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of …
- Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs
- SGLT2 inhibitors in people with and without T2DM
- Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial …
- Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors
- Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors
- SGLT2 inhibitors may offer benefit beyond diabetes
- Liraglutide as add‐on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind …
- Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 …
- SGLT2 inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
- Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
- Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk
- How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European …
- The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
- The effect of SGLT2 inhibitors on cardiovascular events and renal function
- SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
- Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
- Facile synthesis of 1, 2, 3-triazole analogs of SGLT2 inhibitors by ‘click chemistry’
- Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review
- How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Completed and …
- Type 2 diabetes, SGLT2 inhibitors, and glucose secretion
- Use of SGLT2 inhibitors during Ramadan: a survey of physicians’ views and practical guidance
- Euglycemic diabetic ketoacidosis: the clinical concern of SGLT2 inhibitors
- A fluorescent glucose transport assay for screening SGLT2 inhibitors in endogenous SGLT2-expressing HK-2 cells
- Pharmacokinetic/pharmacodynamic properties and clinical use of SGLT2 inhibitors in non-Asian and Asian patients with type 2 diabetes and chronic kidney disease
- SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in Asian versus non-Asian patients
- SGLT2 inhibitors and protection against pancreatic beta cell failure
- Global Mechanisms Proposed for Cardioprotective Effects of SGLT2 inhibitors
- C-Aryl glycoside inhibitors of SGLT2: exploration of sugar modifications including C-5 spirocyclization
- Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543
- SGLT2 inhibitors in Diabetic Kidney Disease
- The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update
- Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
- Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient
- Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative …
- Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
- How does CREDENCE inform best use of SGLT2 inhibitors in CKD?
- Potential place of SGLT2 inhibitors in treatment paradigms for type 2 diabetes mellitus
- Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes
- Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
- Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?
- What next after metformin? Thinking beyond glycaemia: are SGLT2 inhibitors the answer?
- Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists
- The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
- SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
- SGLT2 versus DPP4 inhibitors for type 2 diabetes
- Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
- Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta-analysis
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
- Effects of incretin-based therapies and SGLT2 inhibitors on skeletal health
- 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
- Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners
- The Multiple Effects of SGLT2 inhibitors Suggest Potential Benefit in COVID-19 Patients
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents
- Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19
- Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus
- Recent developments of C-Aryl Glucoside SGLT2 inhibitors
- Are SGLT2 inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?
- Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview
- The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
- Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta …
- A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
- Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 inhibitors
- SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
- Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure
- SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites
- Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents
- Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- … involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in …
- The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
- Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents
- Organ protection beyond glycaemic control with SGLT2 inhibitors
- SGLT2 inhibitors, sodium and off-target effects: an overview
- Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective
- SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
- Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease
- SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
- A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
- SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs
- Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
- The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
- Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
- SCORED and SOLOIST: the next scores for SGLT2 inhibitors
- Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
- Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension
- SGLT2 inhibitors might halt progression of diabetic nephropathy
- Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 inhibitors
- SGLT2 inhibitors race to enter type-2 diabetes market
- SGLT2 inhibitors: diabetic kidney disease and beyond
- … Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors
- Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
- Subtype‐dependent reporting of stroke with SGLT2 inhibitors: implications from a Japanese pharmacovigilance study
- C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents
- SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort …
- SGLT2 inhibitors and all‐cause mortality: a meta‐analysis of randomized controlled trials.
- Syntheses of SGLT2 inhibitors by Ni-and Pd-Catalyzed Fukuyama Coupling Reactions
- Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
- Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases
- Drug–drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes …
- SGLT2 inhibitors—Sweet Success for Diabetic Kidney Disease?
- SGLT2 inhibitors versus DPP4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus
- SGLT2 inhibitors and the risk of diabetic ketoacidosis
- Design, synthesis and in vivo hypoglycemic activity of tetrazole-bearing N-glycosides as SGLT2 inhibitors
- Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study
- How many patients with type 2 diabetes meet the inclusion criteria of the cardiovascular outcome trials with SGLT2 inhibitors? Estimations from a population …
- Novel l-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Treatment of Type 2 Diabetes
- Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 inhibitor Drugs
- Efficacy and safety of SGLT2 inhibitors in reducing glycated hemoglobin and weight in emirati patients with type 2 diabetes
- Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside inhibitors of SGLT2
- SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
- SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review
- SGLT2 inhibitors across the Spectrum of Severity of CKD
- When insulin therapy fails: the impact of SGLT2 inhibitors in patients with type 2 diabetes
- Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
- Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
- The influence of long‐term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney …
- Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study
- Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Synthesis and Biological Evaluation
- Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis
- Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- Use of SGLT2 inhibitors during Ramadan: An expert panel statement
- CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents
- The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
- … to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors
- Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
- Association of SGLT2 inhibitors with outcomes in Type 2 diabetes with reduced and preserved left ventricular ejection fraction—Analysis from the CVD‐REAL 2 Study
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
- Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans
- Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the Yin and Yang of glucagon?
- SGLT2 inhibitors: expanding their Empire beyond diabetes
- SGLT2 inhibitors in development
- SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis
- Use of SGLT2 inhibitors in diabetic renal transplant recipients: a mixed method exploratory exercise
- Recommendations on the proper use of SGLT2 inhibitors
- Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
- Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
- Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors
- Effectiveness and Safety of SGLT2 inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
- SGLT2 inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
- SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
- Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital
- SGLT2 inhibitors and the Mechanisms Involved in Weight Loss
- SGLT2 inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
- Response to comment on Suissa. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 2018; 41: 6–10
- Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for Cardiovascular and Renal Points of View
- Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG
- Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database
- Focused Updates: SGLT2 inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
- SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
- Discovery of Novel N-β-d-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Management of Hyperglycemia in …
- Further insights into SGLT2 inhibitors
- Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors
- SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
- Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of type 2 diabetes
- Design and synthesis of fluorescent SGLT2 inhibitors
- Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 inhibitors: a Nationwide Cohort Study in the USA
- Will SGLT2 inhibitors prove to be a ‘multiple’gamechanger?
- Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors
- When and for Whom Should We Use SGLT2 inhibitors in HFrEF?
- Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control
- Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
- Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an off-label use protocol for clinical practice
- Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new’French paradox’.
- Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes of the adult
- Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure
- The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies
- SGLT2 inhibitors for type 2 diabetes
- SGLT2 inhibitors enter crowded diabetes space
- Renal and cardiac implications of sodium glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
- Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
- GLP-1 Receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection
- Preventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors
- Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
- SGLT2 inhibitors: a narrative review of efficacy and safety
- SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
- Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes
- Remarkable improvement of glucose variability by Sodium–glucose cotransporter 2 (SGLT2) inhibitors using continuous glucose monitoring (CGM)
- Comment on Suissa. Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
- Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection …
- 1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice
- SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial
- Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
- SGLT2 inhibitors in Resistant Hypertension: A Sweet Solution
- Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent
- SGLT2 inhibitors and renal complications in type 1 diabetes
- Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition
- The SGLT2 inhibitors–where are we now?
- Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2 inhibitors: the Gift that Keeps on Giving
- Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly
- Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database
- SGLT2 inhibitors: Who Should Prescribe Them for Patients With Heart Failure?
- Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
- Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled …
- The Pleiotropic Effects of SGLT2 inhibitors: Remodeling the Treatment of Heart Failure
- SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent …
- SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
- Potential role of SGLT2 inhibitors in the management of type 1 diabetes
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review
- Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus
- Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug …
- SGLT2 inhibitors and euglycemic diabetic ketoacidosis
- Repurposing SGLT2 inhibitors
- Chances and risks of SGLT2 inhibitors
- Atom-based 3D QSAR studies on novel N-β-d-xylosylindole derivatives as SGLT2 inhibitors
- Sodium glucose co transporter 2 (SGLT2) inhibitors: a new sword for the treatment of type 2 diabetes mellitus
- We Can Finally Stop Worrying About SGLT2 inhibitors and Acute Kidney Injury
- Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs
- Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
- Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors
- SGLT2–inhibitors trigger downstream mechanisms that may exert adverse effects upon bone
- Use of SGLT2 inhibitors in Older Adults: Scientific Evidence and Practical Aspects
- Bolstering your armamentarium with SGLT2 inhibitors
- Unsweetening the heart: possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects
- Combined HQSAR, topomer CoMFA, homology modeling and docking studies on triazole derivatives as SGLT2 inhibitors
- A Systematic Review of Analytical Profiles of SGLT2 inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus
- Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2–inhibitors and glp1-receptor agonists
- … and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of …
- Why Choose Between SGLT2 inhibitors and GLP1-RA When You Can Use Both? The Time to Act Is Now
- SGLT2 inhibitors: glucotoxicity and tumorigenesis downstream the renal proximal tubule?
- Synthesis of Benzyl C‐Analogues of Dapagliflozin as Potential SGLT2 inhibitors
- Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors
- Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors
- Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
- Effects of SGLT2 inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
- SGLT2 inhibitors Therapy in Type 2 Diabetes Mellitus
- Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening
- When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease
- … causes an increase in endog-enous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 inhibitors on EGP in …
- Development of sodium glucose co-transporter 2 (SGLT2) inhibitors with novel structure by molecular docking and dynamics simulation
- SGLT2 inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database
- P1010 EFFECTS OF SGLT2 inhibitors ON DIABETIC NEPHROPATHY: PODOCYTURIA ON FOCUS
- Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics …
- Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
- The effect of SGLT2 inhibitors on silent myocardial ischemia
- Palladium‐Catalyzed Arylation of Carbasugars Enables the Discovery of Potent and Selective SGLT2 inhibitors
- In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
- Synthetic and biological studies of carbasugar SGLT2 inhibitors
- Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors
- Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
- Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
- Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
- ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2
- Development and recent advancement of SGLT2 inhibitors for the treatment regime of T2DM
- UNDER-PRESCRIPTION OF SGLT2 inhibitors IN PATIENTS WITH DIABETES AND CARDIOVASCULAR DISEASE IN THE UNITED STATES
- The future is now: SGLT2 inhibitors and type 1 diabetes–What about exercise?
- Effects of Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
- SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies
- Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors
- The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation
- A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR …
- The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
- Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy
- 5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- SGLT2 inhibitors in diabetes mellitus treatment
- Possible new inflammatory side-effect of SGLT2–inhibitors: fixed drug eruption
- Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, pramlintide, colesevelam, SGLT2 inhibitors, tagatose, succinobucol
- Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2–inhibitors: a review
- SGLT2 inhibitors: the Gift that Keeps on Giving
- Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors and The Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events
- Correction to “Synthetic Strategies toward SGLT2 inhibitors”
- Renal hemodynamic and protective effects of renoactive drugs in type 2 diabetes: interaction with SGLT2 inhibitors.
- Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
- Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors
- P1038 NEPHROPROTECTIVE EFFECT OF SGLT2 inhibitors DURING FIRST YEAR OF TREATMENT
- The efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study
- Heart Failure Prevention with SGLT2 inhibitors
- Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
- 1124-P: SGLT2 inhibitors as Adjuvant Therapy for Type 1 Diabetes: An Italian Center Experience
- A rose by any other name: ketoacidosis due to SGLT2 inhibitors reveals latent autoimmune diabetes
- The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
- Drugs for diabetes: part 8 SGLT2 inhibitors
- Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study
- C-Aryl 5a-carba-β-D-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- SGLT2 inhibitors-moving on with the evidence.
- … now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement …
- Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors
- Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors
- Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and …
- Effects of SGLT2 inhibitors as an Add-on Therapy to Metformin on Electrocardiographic Indices of Ventricular Repolarization
- Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
- SGLT2 inhibitors suppress NLRP3 inflammasome activity via changes in ketones and insulin in type 2 diabetes and cardiovascular diseases
- Predicting the biological activities of triazole derivatives as SGLT2 inhibitors using multilayer perceptron neural network, support vector machine, and projection …
- Thiadiazole‐based Thioglycosides as Sodium‐glucose Co‐transporter 2 (SGLT2) inhibitors
- Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and …
- Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2
- SGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis
- Conformationally Constrained Spiro C‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) inhibitors
- Mechanistic evaluation of the effect of SGLT2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems …
- … of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors
- 1097-P: Disposition Index Is a Predictor of Urinary Glucose Excretion in Subjects Treated with SGLT2 inhibitors
- Biochemical Interaction Analysis of Natural SGLT2 inhibitors with Alzheimer Targets: A Computational Approach.
- Essentials of SGLT2 inhibitors in Diabetes
- … with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 …
- … Background between Patients with and without Increased Glucagon Secretion while on SGLT2 inhibitors: A Comparison of Canagliflozin and Other SGLT2 inhibitors
- P2484 SGLT2 inhibitors in diabetes with CKD
- Sodium glucose transporter 2 (SGLT2) inhibitors: Current status in clinical practice.
- Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 inhibitors
- Integrated computational approach on sodium-glucose co-transporter 2 (SGLT2) inhibitors for the development of novel antidiabetic agents
- The Effects of SGLT2 inhibitors on Lipid Metabolism. Metabolites 2021, 11, 87
- Sodium-glucose linked transporter 2 (SGLT2) inhibitors—fighting diabetes from a new perspective
- SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
- Real-World Clinical Experience with SGLT2 inhibitors: Use of Special Screening Tool for Type 2 Diabetes Patients to Avoid Serious Adverse Events: A Single-Centre …
- P1047 URICOSURIA AND URINARY GLUCOSE EXCRETION ON DIABETIC KIDNEY DISEASE (DKD) PATIENTES TREATED WITH SGLT2 inhibitors
- Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV
- O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
- SGLT2 inhibitors: a new generation of antidiabetic drugs
- C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type …
- Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors
- Do SGLT2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?
- Acidosis without marked hyperglycemia: Euglycemic diabetic ketoacidosis associated with SGLT2–inhibitors
- Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases
- How low do we fall to lower hemoglobin A1c? SGLT2 inhibitors: Effective drugs or expensive toxins!
- SGLT2 inhibitors and the changing landscape for treatment of diabetes
- Patient and clinical characteristics of heart failure patients concomitantly prescribed SGLT2 inhibitors and sacubitril/valsartan, a database cohort study using the …
- Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors
- 1145-P: SGLT2 inhibitors Improve Day-to-Day Glucose Variability in Patients with Type 1 Diabetes
- Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 inhibitors
- GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
- Cardiovascular benefit of SGLT2 inhibitors in the therapeutics of diabetes mellitus: A close look beyond the horizon
- Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Life-Threatening Complications
- A new and improved process for C-aryl glucoside SGLT2 inhibitors
- Are the protective effects of SGLT2 inhibitors a” class-effect” or are there differences between agents?
- The role of SGLT2 inhibitors in type 2 diabetes
- Risk of DKA with SGLT2 inhibitors
- SGLT2 inhibitors for treatment of type 2 diabetes mellitus: Focus on canagliflozin
- The Role of SGLT2 inhibitors in Vascular Aging
- Effects of SGLT2 inhibitors on Insulin Secretion and Insulin Resistance—Results from a Cross-Sectional Study
- Clinical and Economic Rationale for the Early use of SGLT2 inhibitors in Patients with Type 2 Diabetes
- Sweet success? SGLT2 inhibitors and diabetes
- SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
- SGLT2 inhibitors for type 2 diabetes mellitus treatment
- PDB7 DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 inhibitors: A REAL-WORLD APPROACH
- 141-LB: The Reality of Diabetic Ketoacidosis in Patients with Type 2 Diabetes Using SGLT2 inhibitors Revealed by a Nationwide Claim-Based Database in Japan
- Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
- SGLT2 inhibitors: cardiovascular benefits beyond glycemic control
- P1009 RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 inhibitors
- Efficacy and cardiovascular safety of SGLT2 inhibitors.
- A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF-Letter regarding the article’Baseline Characteristics of Patients with Heart Failure with …
- Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
- Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A …
- Can CMR Elucidate the Cardiovascular Benefit of SGLT2 inhibitors?
- SGLT2 inhibitors and the Risk of Major Adverse Cardiovascular Events: A Multi-database Study Using a Prevalent New-User Design
- β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 inhibitors
- SGLT2 inhibitors and cardiovascular outcomes: Do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
- A paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors.
- Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) during the month of Ramadan in Muslim patients with type 2 diabetes
- Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) inhibitors in Type 2 Diabetes Mellitus
- SGLT2 inhibitors: A Review of Canagliflozin
- … -P: Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 inhibitors …
- Should we be combining GLP-1 receptor agonists and SGLT2 inhibitors in treating diabetes?
- Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment
- SGLT2–inhibitors in type-2 diabetes: The remaining questions!
- 36-OR: Comparative effectiveness of SGLT2 inhibitors vs. GLP-1 agonists
- SGLT2 inhibitors and euglycemic ketoacidosis
- SGLT2 inhibitors: not just another glucose-lowering agent
- Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors
- SGLT2 inhibitors suppress alpha-adrenergic tone and morning elevation of plasma glucose levels
- SGLT2 inhibitors: A revolution in therapeutics of a major Non 3 Communicable Disease 4
- Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
- Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
- RE: Should we stick to SGLT2 inhibitors?
- Role of SGLT2 inhibitors in Heart Failure
- P317 A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study …
- EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY SGLT2 inhibitors AND A KETOGENIC DIET: A CASE SERIES AND REVIEW OF LITERATURE
- SGLT2 inhibitors: a new treatment option for type 2 diabetes
- Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors
- Why Are SGLT2 inhibitors Nephroprotective? Mechanisms of Action And Possible Benefits A Review
- Fournier’s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: Our experience
- Utility of SGLT2 inhibitors in patients with chronic heart failure with diabetes mellitus
- 35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy
- An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus
- Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and stroke …
- Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 inhibitors
- SGLT2–inhibitors
- To Heart “Fail” or Not? The Expanding Role of SGLT2 inhibitors
- SGLT2 inhibitors: Rationale and Perspectives of Use in Heart Failure
- 2275-PUB: Relationship between the Effect of SGLT2 inhibitors and Dietary Intake in Japanese Patients with Type 2 Diabetes
- Extending the Use of SGLT2 inhibitors from Diabetic to Non-diabetic Kidney Disease
- Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
- SGLT2 inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature
- Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
- SGLT2 inhibitors and ketoacidosis: pathophysiology and management
- SGLT2 inhibitors in diabetic and non-diabetic nephropathies
- SGLT2 inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease
- SGLT2 inhibitors
- Real-life prescribing of SGLT2 inhibitors: How to handle other medications, including glucose-lowering drugs and diuretics
- Molecular modeling studies of thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
- Cardiac Energy Metabolism and the Role of SGLT2 inhibitors in Heart Failure
- The position of SGLT2 inhibitors in current medicine.
- The Elevation of Hematocrit after Administration of SGLT2 inhibitors Does Not Correlate with Plasma Osmolarity in Japanese Subjects with Type 2 Diabetes
- FP499 PHARMACODYNAMIC REASON WHY THE DOSE OF SGLT2 inhibitors SHOULD NOT BE REDUCED IN PATIENTS WITH GFR LESS THAN 45 ML/MIN
- SGLT2 inhibitors and Heart Failure Outcomes
- SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus
- gem‐Dimethyl‐bearing C‐Glucosides as Sodium‐glucose Co‐transporter 2 (SGLT2) inhibitors
- 163-LB: Impact of SGLT2 inhibitors on Liver Function Test in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-analysis
- Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors: A Case Report and Review of Literature
- SGLT2 inhibitors-SOMETHING IN THE WATER, OR THE HEART OF THE MATTER?
- EFFECT OF SGLT2 inhibitors ON LIPID PARAMETERS: A META-ANALYSIS OF 30 RANDOMIZED CLINICAL TRIALS AND 10,246 PATIENTS
- 1217-P: The Kidney Effects of the SGLT2 inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
- Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
- SGLT2 inhibitors and diabetic nephropathy: sweet nothings
- SGLT2 inhibitors cost effective versus sulfonylureas in T2DM
- SGLT2 inhibitors, beyond glucose-lowering effect: impact on nephrology clinical practice
- Complementarity between randomised controlled trials and observational registries: the example of cardiovascular prevention with SGLT2 inhibitors
- Recognizing low endogenous insulin production as a precipitating factor of DKA in type-2 diabetic patients taking SGLT2 inhibitors: a case report
- Cost Analysis of SGLT2 inhibitors in patients with type 2 Diabetes in India
- Annals On Call-SGLT2 inhibitors: The Good, the Bad, and the Ugly
- NON-CARDIAL EFFECTS OF SGLT2 inhibitors (REVIEW)
- SGLT2 inhibitors
- SGLT2 inhibitors and their association with balanoposthitis and Fournier’s gangrene.
- 2340-PUB: Success of Online CME at Improving the Clinical Knowledge and Confidence in Using SGLT1/SGLT2 inhibitors in T1D Management
- SGLT2 inhibitors ARE NOT ASSOCIATED WITH RISKS FOR AMPUTATION-A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED …
- Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Stroke―Reply―
- EFFECTS OF SGLT2 inhibitors ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION
- The emerging role of SGLT2 inhibitors in the treatment of type 2 diabetes. Focus on dapagliflozin
- Spiroketal Phthalane C-Glycosides: Synthesis of Papulacandins and SGLT2 inhibitors
- Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men
- Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors
- GLYCEMIC OUTCOMES OF SGLT2 inhibitors IN OVERWEIGHT OR OBESE TYPE 2 DIABETES PATIENTS
- SGLT2 inhibitors in patients with chronic kidney disease: from clinical trials to guidelines and new prospects for clinical practice
- 1227-P: GlycoMark 1, 5-Anhydrocluitol values in patients taking SGLT2 inhibitors
- Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms: A systematic review
- House of Carbs: the path to euglycemic DKA in patients with Diabetes on SGLT2 inhibitors
- Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
- … control and cardiovascular risk factor management in adults with type 2 diabetes with and without chronic kidney disease before SGLT2 inhibitors: Insights from the …
- A Comprehensive Review on various HPLC based Analytical techniques used for the Estimation of SGLT2 inhibitors type of Antidiabetic drugs in various …
- SGLT2 inhibitors compared with sitagliptin as add-on therapy to metformin in type 2 diabetes: a systematic review and meta-analysis
- … Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 inhibitors to the Improvement …
- Therapeutic Potential of SGLT2 inhibitors in Treating Type 2 Diabetes Mellitus
- Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018
- P272 Additional use of SGLT2 inhibitors in the treatment of acute decompensated heart failure may prevent acute kidney injury
- What Are The Benefits In The Association Of SGLT2 inhibitors And Other Drugs?
- … Ali, Muhammad Umer Ahmed, Sundas, Muhammad Aslam Khan, Qalb Khan, Gul Muhammad Memon, Izhan Ali Khan. Role of SGLT2 inhibitors in Heart Failure
- SGLT2 inhibitors in Patients with Diabetes and Cardiovascular Disease
- Minireview: are SGLT2 inhibitors heart savers in diabetes?
- SGLT2 inhibitors: results from clinical practice
- Comment on” comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in …
- Efficiency and safety of SGLT2 inhibitors
- Mechanisms and efficacy of SGLT2 inhibitors
- Reply to Comment: Is there any place for SGLT2–inhibitors in post-liver transplantation patients?
- 101 Heart failure, diabetes and use of SGLT2 inhibitors–a missed opportunity
- Renoprotective Effects of SGLT2 inhibitors
- Leaving the Glucocentric View: Can SGLT2 inhibitors Halt CVD in Patients With Type 2 Diabetes?
- … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
- SGLT2 inhibitors: a focus on cardiac benefits and potential
- A Review on Efficacy and Safety of SGLT2 inhibitors as Add-on Therapy with Metformin
- Sodium glucose co-transporter 2 (SGLT2) inhibitors in type 2 diabetes: a literature review of approved products
- Correction to: Optimising the Benefits of SGLT2 inhibitors for Type 1 Diabetes
- What have we learned from clinical outcome trials with SGLT2 inhibitors?
- Using SGLT2 inhibitors in Special Populations
- The SGLT2 inhibitors-a review: original
- Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors
- CLINCIAL EXPERIENCE WITH THE USE OF SODIUM GLUCOSE TRANSPORTERS SGLT2 inhibitors IN AN ENDOCRIONOLOGY OUTPATIENT CLINIC IN …
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke
- SGLT2 inhibitors, GLP-1 Receptor Agonists, or Bariatric Surgery and Risks of All-Cause Mortality, Cardiovascular Diseases, End-Stage Renal Diseases, and Severe …
- SGLT2 inhibitors in Diabetes mellitus
- SGLT2 inhibitors Continue to Show Kidney, Heart Benefits
- 156-OR: Risk-Benefit of SGLT2 inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
- The Benefits of SGLT2 inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
- Comparative Cardiovascular Effectiveness of SGLT2 inhibitors vs. Liraglutide in Routine Care
- The Role of SGLT2 inhibitors in Clinical Practice
- SGLT2 inhibitors and Renal Outcomes
- SGLT2 inhibitors for Treating Diabetes
- 2363-PUB: The efficacy of low vs. high FDA-approved SGLT2 inhibitor dose compared with DPP-4 inhibitors: a meta-analysis
- SUN-177 house of Carbs: the path to euglycemic Dka in patients with diabetes on SGLT2 inhibitors
- Sodium Glucose Co-transporter Type 2 (SGLT2) inhibitors in CKD
- PRETREATMENT WITH SGLT2 inhibitors AMELIORATES CONTRAST-INDUCED NEPHROPATHY
- Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and …
- Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
- Euglycemic ketoacidosis: a complication of SGLT2 inhibitors
- Cardioprotective and Renoprotective Effects of the Use of SGLT2 inhibitors in Diabetes Mellitus Patients
- Predicting the Need for SGLT2 inhibitors for Future Heart Failure
- Model-based meta-analysis of glucosuria-related adverse events in SGLT2 inhibitors
- Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
- Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
- SUN-181 case report: rare complication of SGLT2 inhibitors can occur only 10 days after starting the medication
- 2343-PUB: reduction of HbA1c after SGLT2 inhibitors correlate with change in plasma osmolarity but not with elevation of hematocrit in Japanese patients with type 2 …
- P2521 Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a …
- A Significance of Sodium-Glucose Cotransporter 1 (SGLT1) Inhibition by SGLT2 inhibitors
- FP408 NOVEL MOLECULAR MECHANISMS IN THE RENOPROTECTIVE EFFECT OF SGLT2 inhibitors VIA MITIGATION OF TUBULAR HYPOXIA AND PROTEIN …
- Impact of SGLT2 inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group
- Combination therapy with once weekly GLP 1 receptor agonist dulaglutide and SGLT2 inhibitors in Asian Indians with type 2 diabetes
- … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
- Effects of Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors on Major Cardiovascular Events in Type 2 Diabetic Patients a Meta-Analysis of Randomized …
- THE ROLE OF SGLT2 inhibitors IN TYPE 2 DIABETES
- Erratum. SGLT2 inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018; 41: 1543 …
- Exploration of novel C-glucoside formation and application for SGLT2 inhibitors-Discovery of canagliflozin as a SGL T2 inhibitor
- Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes.
- Os 32-05 Effects of SGLT2 inhibitors on circadian rhythm of blood pressure in rats
- 2300-PUB: The Efficacy and Safety of Combinations of SGLT2 inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: A Systematic Review and …
- The Use of SGLT2 inhibitors in Elderly Patients with Type 2 Diabetes Mellitus
- SGLT2 inhibitors: Now The Bad News
- A Comparison of the Effects of SGLT2 inhibitors in Heart Failure Patients with Diabetes Versus Non-diabetic Patients
- SGLT2 inhibitors for type 2 diabetes: Clinical considerations
- SGLT2 inhibitors and kidney outcomes in the real world
- A NOVEL ROLE OF SGLT2 inhibitors TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND …
- 1, 2, 4-Triazinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
- Effectiveness and safety of SGLT2 inhibitors compared to dipeptidyl peptidase (DPP)-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based …
- SGLT2 inhibitors in T2D and associated comorbidities-differentiating within the class: correspondence
- SGLT2 inhibitors Reduce Blood Pressure and Left Ventricular Mass
- SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
- The Renoprotective Effects of SGLT2 inhibitors versus Placebo in Patients with Type 2 Diabetes with or
- Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 inhibitors in Type 2 Diabetes Management: Key Evidence and …
- Comparative Cardiovascular Efficacy of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 Agonists—A Network Meta-analysis
- A New Weapon in the Fight Against Diabetes: SGLT2 inhibitors
- Assimilating the Evidence in T2DM Cardiovascular and Renal Outcomes With SGLT2 inhibitors Daniel Einhorn, MD, FACE, FACP; Serge A. Jabbour, MD, FACP …
- 1431-P: Risk of Venous Thromboembolism amongst Initiators of SGLT2 inhibitors Compared with Other Glucose-Lowering Agents
- 2218-PUB: Initiation of SGLT2 inhibitors in Hospitalized Patients with CVD
- Cardiovascular safety of SGLT2 inhibitors
- Effects and Safety of SGLT2 inhibitors on Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of …
- Erratum to: practical approach to initiating SGLT2 inhibitors in type 2 diabetes
- … Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 inhibitors, GLP-1 Receptor Agonists, and SGLT2 inhibitors
- Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 inhibitors
- Persistence to Treatment with DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1-RAs Compared with Insulin after Failure with First Antidiabetic Drug in T2DM Patients
- 1162-P: Coverage, Formulary Restrictions, and Average Retail Prices of SGLT2 inhibitors and GLP-1 Receptor Agonists across Medicare Part D Plans in 2019
- COMPARISON OF EFFECTIVENESS OF SGLT2 inhibitors IN THE INDIAN MULTI ETHINIC TYPE 2 DIABETES PATIENTS-REAL WORLD EXPERIENCE
- Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
- SGLT2 inhibitors REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS IN TYPE 2 DIABETIC PATIENTS: A META-ANALYSIS OF RANDOMIZED …
- SGLT2–inhibitors in the Management of Type 2 Diabetes
- SGLT2 inhibitors and risk of genitourinary infections
- The combination of GLP-1 analogs and SGLT2 inhibitors: new perspectives?
- Synthetic Studies towards Carbocyclic Analogues of SGLT2 inhibitors
- 1211-P: Real-World Use of SGLT2 inhibitors in a Large US Safety-Net Health System
- Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription
- The use of SGLT2 inhibitors compared to GLP-1 receptor agonists in patients with type 2 diabetes and hypertension
- SGLT2 inhibitors and Ketoacidosis: Cause for Concern?
- SGLT2 inhibitors–Is the Paradigm in Type 2 Diabetes Mellitus Management Changing?
- MON-170 OUTCOMES OF SGLT2 inhibitors USE IN DIABETIC RENAL TRANSPLANT PATIENTS-SINGLE CENTER EXPERIENCE
- SAT-298 EFFECT OF SGLT2 inhibitors ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS …
- Frequently asked questions: SGLT2 inhibitors–a novel approach to managing hyperglycaemia
- Predictors of response to SGLT2–inhibitors and DPP4-inhibitors: a MASTERMIND stratified medicine study
- SGLT2 inhibitors and the Risk of Ketoacidosis in Patients With Type 2 Diabetes
- 172 Untold Story of SGLT2 inhibitors
- … of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) inhibitors: A …
- Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
- 34-OR: SGLT2 inhibitors: A Comparison of Cardiovascular, Medical, and Cost Outcomes
- Glucose Lowering Effect of SGLT2 inhibitors: A Review of Clinical Studies.
- SGLT2 inhibitors Increase Bone Strength by Increasing Procollagen Type 1 Amino-Terminal Propeptide in Patients with Type 2 Diabetes
- 081 Assessment of SGLT2 inhibitors use in Heart Failure Patients at a Tertiary Hospital
- “The Proof is in the Pudding”: Do SGLT2 inhibitors Cause Diabetic Ketoacidosis?
- SGLT2 inhibitors protect against MACE, suggests meta-analysis
- 1200-P: Use of SGLT2 inhibitors in Hospitalized Patients in an Academic Center
- Real-life clinical experience with GLP1 analogs and SGLT2 inhibitors in the treatment of diabetes type 2 and obesity
- Meta-analysis of SGLT2 inhibitors and stroke risk in type 2 diabetic patients
- APPLICATION OF THE MINIMAL MODEL IN SUBJECTS TREATED WITH SGLT2 inhibitors
- SGLT2 inhibitors: A Novel Therapy for Type 2 Diabetes Mellitus
- www. OpenCME. org/course/where-do-SGLT2–inhibitors-fit-spectrum-of-treatment-of-t2dm
- Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 inhibitors in Type 2 DM Subjects
- Letter to the Editor: Sodium‐glucose cotransporter 2 inhibitors (SGLT2‐I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes
- Effects of SGLT2 inhibitors in the treatment of a population with type 2 diabetes mellitus
- Efficacy of SGLT2 inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
- SGLT2 inhibitors–new oral hypoglycemic drugs inhibitory SGLT2–nowe doustne leki przeciwcukrzycowe
- Relation Between HbA1c Level and Effectiveness of SGLT2 inhibitors in Diabetic Patients With Acute Decompensated Heart Failure
- SGLT2 inhibitors Associated With Lower-Extremity Amputation Among Patients With Type 2 Diabetes
- 137-LB: Early Performance Under SGLT2 inhibitors in High-Risk Patients: EARLY PUSH Study: A Prospective Double-Blind Comparative Study
- Maximizing Patient Safety with Newly Approved Therapies: Focus on SGLT2 inhibitors
- MHRA drug safety update: risk of Fournier’s gangrene with SGLT2 inhibitors for diabetes
- The Positive Effect of the Combination of GLP-1 Analogues and SGLT2 inhibitors on Obese Patients with Noninsulin-Treated DM2
- Letter to the Editor: Comment on “SGLT2 inhibitors may predispose to ketoacidosis” by Taylor SI, et al
- Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 inhibitors—Analysis from the CVD-REAL 2 Study
- SGLT2 inhibitors as adjunct therapy to insulin in type 1 diabetes: Meta analysis
- The Role of SGLT2 inhibitors and DPP4 inhibitors in Preventing Diabetic Nephropathy
- The metabolic effects of SGLT2 inhibitors-Does the increase in ketone bodies protect the heart?
- Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes
- Effect of SGLT2 inhibitors on glucagon secretion in pancreatic alpha cells
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors renal benefits and beyond
- Use of Sodium-Glucose Co-Transporter-2-inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation.
- Sodium Glucose Cotransporter-2 inhibitors (SGLT2 inhibitors)
- The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes
- 2354-PUB: Estimating Improvement of TGF Mechanism from Changes of Urinary Glucose and Sodium Excretion by SGLT2 inhibitors
- Erratum to: sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
- Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Cardiovascular Disease: A Systematic Review
- Methods of producing C-aryl glucoside SGLT2 inhibitors
- … COTRANSPORTER-2 (SGLT2) inhibitors, GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE 4 (DPP-4) inhibitors …
- Cover Feature: Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes (Chem. Eur. J. 12/2018)
- Evaluating Drug Cost per Response with SGLT2 inhibitors in Patients with Type 2 Diabetes Mellitus
- An Overview On Aryl C-glycosides As SGLT2 inhibitors With Antidiabetic Potential.
- SGLT2 inhibitors for gout: Do these antihyperglycaemic agents reduce uric acid levels?
- SGLT2 inhibitors IN KETOACIDOSIS: THE CULPRIT OR AN INNOCENT BYSTANDER?
- Improved preparation of C-aryl glucoside SGLT2 inhibitors
- Efficacy and Usefulness of SGLT2 inhibitors in Niddm Patients on the Backdrop of Metformin and Sulphonyl Urea
- Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
- 1141-P: Effects of SGLT2 inhibitors on Nighttime Sympathetic Nerve Activity, Heart Rate, Blood Pressure Variability, and Glycemic Variability in Type 2 Diabetic …
- ASSESSMENT OF SGLT2 inhibitors ON KIDNEY MORPHOLOGY AND ALBUMIN EXCRETION IN RATS WITH EXPERIMENTAL DIABETES MELLITUS TYPE 1.
- An audit of SGLT2–inhibitors in the management of type 2 diabetes in Sligo University Hospital Ireland: metabolic and haemodynamic outcomes
- Euglycemic diabetic ketoacidosis in type 2-diabetes mellitus treated with SGLT2 inhibitors-a report on two cases
- SGLT2 inhibitors for Type 2 Diabetes Mellitus Treatment SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering …
- Incidence of Heart Failure Hospital Admissions Among Type 2 Diabetes Mellitus Patients and the Potential Impact of SGLT2 inhibitors in Japan: A Population-based …
- A survey of various adjuvant treatments used against type 1 diabetes, focusing on SGLT2 inhibitors
- Potential Unrealized Mortality Benefit of GLP-1 Receptor Agonists and SGLT2 inhibitors: A Report from the Veterans Health Administration Clinical Assessment …
- Cardiorenal protection with SGLT2 inhibitors (gliflozins): from EMPA-REG OUTCOME to CANVAS
- Prevalence of psychiatric comorbidities in diabetic patients who are candidates for therapy with SGLT2 inhibitors: clinical and metabolic characteristics
- Meet the SGLT2 inhibitors: these new type 2 diabetes medications block glucose reabsorption by the kidneys
- Disparities in the prescribing of DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 analogues in UK primary care
- 2350-PUB: Renoprotective Effects of SGLT2 inhibitors in Japanese Real-World Clinical Practice
- 1433-P: Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 …
- FP451 SIGNIFICANCE OF RENAL AUTONOMIC NERVES FOR WEIGHT-REDUCTION BY SGLT2 inhibitors
- 676-P: Ideal Ketone Test Training among Type 1 Patients in Context of Risk Associated with SGLT2 inhibitors
- Case of Euglycemic Ketoacidosis Induced by SGLT2 inhibitors (Sodium-Glucose Cotransporter 2) in a Diabetic Patient
- Comparative Effectiveness of SGLT2 inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes
- 247-OR: Real-World Effectiveness of SGLT2 inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease
- Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors and their role in Type 1 Diabetes
- Evolving physicians’ perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting
- 1115-P: Comparative Rate of Amputations among Type 2 Diabetes Patients Starting Different SGLT2 inhibitors
- Rates of myocardial infarction and stroke in patients initiated on SGLT2–inhibitors versus other glucose-lowering agents in real-world clinical practice: results …
- REVIEW OF EFFICACY AND SHORT TERM SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) inhibitors USE IN DIABETIC RENAL TRANSPLANT …
- Potential Harmful Effects of The Novel Anti-Diabetics, inhibitors of Sodium-Glucose Cotransporters SGLT1 and SGLT2
- 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
- Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action
- 1962-P: Comparison of the Effects of Three SGLT2 inhibitors on Metabolic Parameters and Insulin Sensitivity in a Nondiabetic Rat Model of Metabolic Syndrome
- 2347-PUB: Relationship between Aging and Effects of SGLT2 inhibitors on Glucose and Lipid Metabolisms and Hepatic Function in Japanese Patients with Type 2 …
- OR22-1 Liraglutide as Add-on to SGLT2 inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double …
- SUN-155 Clinical Experience of SGLT2 inhibitors in a Hispanic Population: Should We Consider Its Use as Add-On Treatment?
- … therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
- Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors
- Control of Blood Glucose with Sodium Glucose Co-transporter 2 (SGLT2) inhibitors Among Patients with Type 2 Diabetes Mellitus
- Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors: Comparing Trial and Real World Use (Study Protocol)
- Sodium Glucose Cotransporter 2 (SGLT2) inhibitors: New drug class in the treatment of Heart Failure with Reduced Ejection Fraction—DAPA-HF and …
- COMPARATIVE EFFICACY OF 3 SGLT2 inhibitors AS THE FIFTH DRUG IN THE MANAGEMENT OF TYPE 2 DM IN ASIAN INDIANS NOT CONTROLLED WITH …
- 25-LB: SGLT2 inhibitors Are Renoprotective via Mitigation of Tubular Hypoxia and Protein O-GlcNAcylation
- Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors Drug Class Review
- Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention …
- … in type 2 diabetes: harnessing individual-level trial data alongside routine care records to identify predictors of response to SGLT2 inhibitors and DPP4 inhibitors
- Health Expenditure Comparison of Diabetic Patients on Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Vs Dipeptidyl Peptidase-4 (DPP4) inhibitors
- Type 2 Diabetes, SGLT2 inhibitors, and Glucose Secretion
- National prevalence of heart failure in type 2 diabetes patients derived from the National eHealth System and their access to treatment with SGLT2 inhibitors or GLP-1 …
- Class Update: Sodium-glucose Cotransporter 2 (SGLT2) inhibitors
- [PP. 05.19] EFFECTS OF SGLT2 inhibitors ON BLOOD PRESSURE, BAPWV, CAROTID ARTERIAL IMT AND ELASTIC MODULUS IN TYPE 2 DIABETIC …
- The efficacy and safety of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- Non-severe hypoglycemia risk difference between sulfonylurea and sodium-glucose cotransporter-2 inhibitors (SGLT2-I) as an add-on to metformin in …
- Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or …
- Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Cardiovascular Disease: A Systematic
- SYSTEMATIC REVIEW OF SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) inhibitors IN THE TREATMENT FOR PATIENTS WITH DIABETES …
- Sodium Glucose Co transporter 2 (SGLT2) inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
- … of autonomous aldosterone secretion in patients with type 2 Diabetes Mellitus and arterial hypertension. The effect of SGLT2 inhibitors on renin-angiotensin …
- A Five Featured Pharmacophore Model for the Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) inhibitors
- SY 10-3 SGLT2 inhibitors AS POTENTIAL ANTIHYPERTENSIVE AND RENOPROTECTIVE AGENTS
- SY 10-2 THE ROLE OF SGLT2 inhibitors IN THE MANAGEMENT OF T2DM
- PS 11-73 BLOOD PRESSURE AND BODY WEIGHT LOWERING EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORT 2 (SGLT2) inhibitors.
- The position of new antidiabetics in clinical practice: SGLT2 vs DPP4 inhibitors
- 5, 5-Difluoro-and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors
- Systematic Review of SGLT2 Receptor inhibitors in dual or triple therapy in type 2 diabetes
- SGLT2 versus DPP4 inhibitors for Type 2 Diabetes: A Meta-analysis
- Audit on sodium glucose cotransporter-2 inhibitors (SGLT2) at Nottingham University Hospitals
- Empagliflozin-the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type
